Lupus Treatment Shows Improved Disease Control in Phase 3 Study

A Phase 3 clinical trial for dapirolizumab pegol, an investigational CD40 ligand inhibitor, demonstrated significant improvements in disease control for patients with moderate-to-severe systemic lupus erythematosus. The study also indicated a positive trend in lowering the need for glucocorticoids. These results offer a potential new therapeutic option for managing lupus.